Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma

PURPOSE: This phase III open-label study compared the efficacy and safety of enzastaurin versus lomustine in patients with recurrent glioblastoma (WHO grade 4). PATIENTS AND METHODS: Patients were randomly assigned 2:1 to receive 6-week cycles of enzastaurin 500 mg/d (1,125-mg loading dose, day 1) o...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Wick, Wolfgang, Puduvalli, Vinay K., Chamberlain, Marc C., van den Bent, Martin J., Carpentier, Antoine F., Cher, Lawrence M., Mason, Warren, Weller, Michael, Hong, Shengyan, Musib, Luna, Liepa, Astra M., Thornton, Donald E., Fine, Howard A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Clinical Oncology 2010
Gaiak:
Original Reports
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2834468/
https://ncbi.nlm.nih.gov/pubmed/20124186
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.23.2595
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak